EMPOWER YOUR RESEARCH
OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com techsupport@origene.com

## Product datasheet for TA322431

## BRCA1 Rabbit Polyclonal Antibody

## Product data:

Product Type: Primary Antibodies
Applications: IHC, WB
Recommended Dilution: WB: 1:500-1000, IHC: 1:50-100
Reactivity:
Modifications: Phospho-specific
Host:
Isotype:
Clonality:
Rabbit
IgG
Polyclonal
Immunogen: Peptide sequence around phosphorylation site of serine 1423 (H-G-S(p)-Q-P) derived from Human BRCA1.

Formulation: PBS pH7.3, 0.05\% NaN3, 50\% glycerol
Concentration: lot specific
Purification: Antigen affinity purification
Conjugation: Unconjugated
Storage:
Stability:
Predicted Protein Size:
Gene Name:
Database Link:
Store at $-20^{\circ} \mathrm{C}$ as received.
Stable for 12 months from date of receipt.
208 kDa
BRCA1, DNA repair associated
NP 009225
Entrez Gene 672 Human
P38398

## Background:

Synonyms:
Protein Families:
Protein Pathways:
Product images:

The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation

BRCAI; BRCC1; BROVCA1; FANCS; IRIS; PNCA4; PPP1R53; PSCP; RNF53
Druggable Genome, Transcription Factors
Ubiquitin mediated proteolysis


Predicted band size: 208 kDa. Positive control: HT29 cells untreated or treated with Anisomycin lysate. Recommended dilution: 1/ 500-1000. (Gel: 8\%SDS-PAGE Lane 1: HT29 cells untreated with Anisomycin lysate Lane 2: HT29 cells treated with Anisomycin lysate Lysates: 30 ug per lane Primary antibody: 1/500 dilution Secondary antibody: Goat anti Rabbit IgG - H\&L (HRP) at 1/10000 dilution Exposure time: 1 minute)


Predicted cell location: Cytoplasm; Nucleus.
Positive control: Human breast carcinoma tissue.
Recommended dilution: 1/ 50-100 The image on the left is immunohistochemistry of paraffinembedded human breast carcinoma tissue using BRCA1 (Phospho-Ser1423) antibody at dilution $1 / 50$, on the right is treated with the synthetic peptide. (Original magnification:x200)

